Incyte Corporation

United States of America

 
Total IP 978
Total IP Rank # 1,361
IP Activity Score 3.5/5.0    674
IP Activity Rank # 1,062
Stock Symbol
ISIN US45337C1027
Market Cap. 14,600M  (USD)
Industry Biotechnology
Sector Healthcare
Dominant Nice Class Pharmaceutical, veterinary and s...

Patents

Trademarks

564 0
101 0
311 0
2
 
Last Patent 2025 - Anti-cd19 therapy in combination...
First Patent 1995 - Chemokine panec-1 polynucleotide...
Last Trademark 2010 - BALRUXA
First Trademark 2010 - ETRAMEZ

Industry (Nice Classification)

Latest Inventions, Goods, Services

2024 Invention Sustained-release dosage forms of ruxolitinib. The present invention relates to sustained-releas...
Invention Ruxolitinib for the treatment of prurigo nodularis. This disclosure relates to ruxolitinib, or a...
Invention Solid forms of jak inhibitor and process of preparing the same. The present disclosure is relate...
Invention Solid forms of an fgfr inhibitor and processes for preparing the same. The present disclosure re...
Invention Bicyclic dgk inhibitors. The present application provides bicyclic compounds that modulate the a...
Invention Bicyclic dgk inhibitors. The present application provides bicyclic compounds that modulate the ac...
Invention Bicyclic heterocycles as mrgprx2 antagonists. The present disclosure relates to bicyclic heterocy...
Invention Process of preparing a pd-1/pd-l1 inhibitor. The present invention relates to processes of prepa...
Invention Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 r...
Invention Bicyclic heterocycles as fgfr inhibitors. The present invention relates to bicyclic heterocycles...
Invention Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma. Th...
Invention Process and intermediates for preparing a jak inhibitor. The present disclosure is related to pr...
Invention Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy. Disclosed are combi...
Invention Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors. The present application provid...
Invention Triazolopyrimidines as a2a / a2b inhibitors. This application relates to compounds of Formula (I...
Invention Salts of a pim kinase inhibitor. The present invention relates to salt forms of the Pim kinase i...
Invention Bicyclic amines as cdk2 inhibitors. The present application provides bicyclic amines of Formula ...
Invention Bicyclic amines as cdk2 inhibitors. The present application provides bicyclic amines of Formula (...
Invention Pyrazoloquinoline kras inhibitors. Disclosed are compounds of Formula I, methods of using the co...
Invention Salts of an fgfr inhibitor. The present invention relates to salt forms of the Fibroblast Growth...
Invention Topical ruxolitinib foam. The present disclosure is directed to foamable composition suitable fo...
Invention Topical ruxolitinib foam. 16-1816-18 fatty alcohols, and an emulsifier component. The present dis...
Invention Anti-cd73 antibodies and uses thereof. Anti-CD73 antibodies are disclosed. Also disclosed are re...
Invention Macrocyclic kinase inhibitors. The present application provides macrocyclic compounds that modul...
Invention Jak inhibitor with a vitamin d analog for treatment of skin diseases. The present disclosure rel...
Invention Vinyl imidazole compounds as inhibitors of kras. Disclosed are compounds of Formula I, methods o...
Invention Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)....
Invention 2-azabicyclo[2.2.1]heptane kras inhibitors. Disclosed are compounds of Formula (I), methods of u...
Invention 2-azabicyclo[2.2.1]heptane kras inhibitors. Disclosed are compounds of Formula (I), methods of us...
Invention Pyrrolidine kras inhibitors. Disclosed are compounds of Formula (I), methods of using the compou...
Invention Cyclic urea kras inhibitors. Disclosed are compounds of Formula (I), methods of using the compou...
Invention Pyrrolidine kras inhibitors. Disclosed are compounds of Formula (I), methods of using the compoun...
Invention Use of an anti-tgfbetar2/pd-1 bispecific antibody to treat cancer. The present disclosure describ...
Invention Use of an anti-tgfßr2/pd-1 bispecific antibody. The present disclosure describes a bispecific an...
Invention Novel pd-1 binding domains. The present disclosure relates to novel PD-1 binding domains that ha...
Invention Fused pyrazine derivatives as a2a / a2b inhibitors. This application relates to compounds of For...
Invention Jak1 pathway inhibitors for the treatment of asthma. This disclosure relates to JAK1 pathway inh...
Invention Bicyclic ureas as kinase inhibitors. The present application provides bicyclic urea compounds th...
Invention Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active age...
Invention Jak1 pathway inhibitors for the treatment of vitiligo. This disclosure relates to JAK1 pathway i...
Invention Combinations and uses thereof. The present disclosure describes a pharmaceutical combination of ...
Invention Quinoline compounds as inhibitors of kras. Disclosed are compounds of Formula I, methods of usin...
Invention Aminopyrazine diol compounds as pi3k-y inhibitors. This application relates to compounds of Form...
Invention Formulations of an axl/mer inhibitor. The present application relates to pharmaceutical formulat...
2023 Invention Pyrazolopyridine compounds and uses thereof. Disclosed are compounds of Formula (I), methods of ...
2022 Invention Anti-b7-h4 antibodies and uses thereof. Anti-B7-H4 antibodies are disclosed. Also disclosed are ...
2010 G/S Pharmaceutical preparations for use in the treatment of oncological, hematological and inflammato...